These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 10472353)
21. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359 [TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen kinetics in localized and advanced prostate cancer. Fitzpatrick JM; Banu E; Oudard S BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674 [TBL] [Abstract][Full Text] [Related]
23. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862 [TBL] [Abstract][Full Text] [Related]
24. [Markers for diagnosis, prediction and prognosis of prostate cancer]. Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854 [TBL] [Abstract][Full Text] [Related]
25. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients]. Leibovitch I; Pinthus Y; Sella BA; Ramon J Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720 [TBL] [Abstract][Full Text] [Related]
26. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361 [TBL] [Abstract][Full Text] [Related]
27. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
28. Prostate biopsy: who, how and when. An update. Djavan B; Milani S; Remzi M Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies. Stewart J; Fleshner N; Cole H; Toi A; Sweet J J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427 [TBL] [Abstract][Full Text] [Related]
31. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level]. Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587 [TBL] [Abstract][Full Text] [Related]
32. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525 [TBL] [Abstract][Full Text] [Related]
33. Phyllodes tumor of the prostate: long-term followup study of 23 cases. Bostwick DG; Hossain D; Qian J; Neumann RM; Yang P; Young RH; di Sant'agnese PA; Jones EC J Urol; 2004 Sep; 172(3):894-9. PubMed ID: 15310992 [TBL] [Abstract][Full Text] [Related]
34. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072 [TBL] [Abstract][Full Text] [Related]
35. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693 [TBL] [Abstract][Full Text] [Related]
36. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754 [TBL] [Abstract][Full Text] [Related]
37. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
38. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Man YG; Gardner WA Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698 [TBL] [Abstract][Full Text] [Related]
39. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346 [TBL] [Abstract][Full Text] [Related]
40. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression. Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]